-

Bayer Appoints Two New Members to U.S. Country Leadership Team

Brian Branca Named Bayer U.S. Chief Financial Officer

Marina Hong named SVP, Head of Human Resources U.S.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, one of the country’s leading life-sciences companies, today announced two changes to its U.S. Country Leadership Team.

Brian Branca has been appointed to the position of Bayer U.S. Chief Financial Officer (CFO), effective June 1, 2022. Branca has been with Bayer since 2006 and most recently served as Bayer U.S. Vice President and Treasurer. He has held numerous financial leadership roles throughout his tenure with the company, including serving as CFO for the Climate Corporation and holding multiple finance functional leadership roles. Branca fills this open role following former U.S. CFO Kelly Gast, who assumed the position of Bayer Crop Science CFO earlier this year.

Marina Hong has been named Senior Vice President and Head of U.S. Human Resources (HR), effective June 6, 2022. Marina joined the company in 2021 as Vice President, Human Resources for Bayer Pharmaceuticals Americas, leading Human Resources for the Americas Pharmaceuticals organization. She brings more than 20 years of HR leadership experience, having served in roles that span almost every function within HR across the U.S., Europe, and Asia.

Both Branca and Hong will report to Patrick Lockwood-Taylor, President of Bayer U.S. and President, Consumer Health, North America. They also join the U.S. Country Leadership Team.

Lisa Massa, current Head of U.S. Human Resources, will retire in July 2022. Lockwood-Taylor recognized Massa for her contributions to Bayer.

“We wish Lisa all the best in her retirement and thank her for her successful leadership and contributions to support the growth of Bayer U.S. and our talented workforce,” said Lockwood-Taylor.

“Both of these appointments are critical as we accelerate our transformation as top-tier U.S. life-sciences company and further our ambition to create a world of Health for All, Hunger for None,” Lockwood-Taylor continued. “Brian and Marina have a depth and breadth of experience to drive excellence in their respective fields, and both will play key roles in leading the company’s performance in its most important market – the U.S. – and achieving the goals of our Growth Strategy.”

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.

Social Media Channels

- Facebook: BayerUnitedStates

- Twitter: BayerUS

- Instagram: BayerUS

- YouTube: BayerUS

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

Nicole Hayes
Bayer U.S.
Email: Nicole.hayes@bayer.com
Mobile: 201-421-5268

Bayer


Release Versions

Contacts

Nicole Hayes
Bayer U.S.
Email: Nicole.hayes@bayer.com
Mobile: 201-421-5268

More News From Bayer

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigat...

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction...

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women. NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, due to an imbalance between estrogen and progesterone levels. This condition is classified as nonatypical as the cells...
Back to Newsroom